Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study

Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study

BACKGROUND:<br>Familial hypercholesterolaemia (FH) is an inherited lipid disorder causing premature heart disease, which is severely underdiagnosed. Improving the identification of people with FH in primary care settings would help to reduce avoidable heart attacks and early deaths. AIM:To eva...

Detaylı Bibliyografya
Asıl Yazarlar:	Akyea, RK, Qureshi, N, Kai, J, de Lusignan, S, Sherlock, J, McGee, C, Weng, S
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Royal College of General Practitioners 2020

Benzer Materyaller

Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study
Yazar:: Ralph K Akyea, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Detection of familial hypercholesterolaemia: external validation of the FAMCAT clinical case-finding algorithm to identify patients in primary care
Yazar:: Stephen Weng, PhD, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care
Yazar:: Joe Kai, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Performance and clinical utility of supervised machine-learning approaches in detecting familial hypercholesterolaemia in primary care
Yazar:: Ralph K. Akyea, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care
Yazar:: Joe Kai, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Familial hypercholesterolaemia
Yazar:: D.J. Blom
Baskı/Yayın Bilgisi: (2011-01-01)

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
Yazar:: Minhas, R, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Reducing Premature Coronary Artery Disease in Malaysia by Early Identification of Familial Hypercholesterolemia Using the Familial Hypercholesterolemia Case Ascertainment Tool (FAMCAT): Protocol for a Mixed Methods Evaluation Study
Yazar:: Anis Safura Ramli, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Familial hypercholesterolaemia.
Yazar:: Gill, P, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Statins and familial hypercholesterolaemia.
Yazar:: Neil, A, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
Yazar:: Nadeem Qureshi, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

EASILY MISSED? Familial hypercholesterolaemia
Yazar:: Gill, P, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Familial Hypercholesterolaemia: An Updated Overall Management
Yazar:: Mohd Kasim, Noor Alicezah, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Yazar:: Vallejo-Vaz, Antonio J., ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Familial Hypercholesterolaemia – a targeted Next Generation Sequencing panel and retrospective analysis of patients with no previously identified pathogenic variant
Yazar:: E. Willis, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Yazar:: Marks, D, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Novel molecular therapies for the treatment of familial hypercholesterolaemia
Yazar:: Kerr, A
Baskı/Yayın Bilgisi: (2016)

International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia
Yazar:: Gerald F. Watts, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis
Yazar:: Anastasia V. Poznyak, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Dietary intervention for children and adolescents with familial hypercholesterolaemia
Yazar:: Maria Elena Capra, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Lomitapide hepatic safety: A long-term retrospective analysis in patients with homozygous familial hypercholesterolaemia
Yazar:: J. Cegla, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

The utility of DNA-based testing in patients with familial hypercholesterolaemia in the UK
Yazar:: Humphries, SE, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

A perspective for sequencing familial hypercholesterolaemia in African Americans
Yazar:: Wright, Michelle L, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Commentary: What's so special about familial hypercholesterolaemia?
Yazar:: Mant, D
Baskı/Yayın Bilgisi: (2009)

Recent advances in the management and implementation of care for familial hypercholesterolaemia
Yazar:: Nick S.R. Lan, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Hypercholesterolaemia treatment in a patient with family hypercholesterolaemia and myopathy due to carnitine palmitoyltransferase II deficiency with PCSK9 inhibitors
Yazar:: P. Luque Linero, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

Assessment of GENinCode in the Diagnosis of Patients with Suspected Familial Hypercholesterolaemia
Yazar:: P.E. Carey, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

An investigation into any correlation between Single Nucleotide Polymorphism (SNP) score and Welsh score in Familial Hypercholesterolaemia patients and those with polygenic hypercholesterolaemia
Yazar:: J. Webster, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Prevalence and management of familial hypercholesterolaemia in patients with chest pain admitted to hospital: a retrospective observational study
Yazar:: Merete Heitmann, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

Inclisiran for the treatment of hypercholesterolaemia
Yazar:: Joel C Marrs, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition?
Yazar:: S.E. Humphries, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
Yazar:: Marks, D, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.
Yazar:: Marks, D, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Triple-combined hypolipidaemic therapy in familial hypercholesterolaemia: clinical cases
Yazar:: Svetlana A. Chepurnenko, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Cardiovascular Disease Risk Estimation in Mutation Confirmed Familial Hypercholesterolaemia
Yazar:: E. Ofagbor, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Genetics in familial hypercholesterolaemia – from genetic research to new guidelines
Yazar:: Edyta Kinga Prokop, ve diğerleri
Baskı/Yayın Bilgisi: (2019-04-01)

Overview of a collaborative global effort to address the burden of familial hypercholesterolaemia
Yazar:: Alexander R.M. Lyons, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Yazar:: Neil, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Yazar:: Neil, H, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
Yazar:: Neil, H, ve diğerleri
Baskı/Yayın Bilgisi: (2004)